Lakatos L, Szabó I, Csáthy L
Department of Paediatrics, Kenézy Gyula County Hospital, Debrecen, Hungary.
Acta Paediatr Scand Suppl. 1989;360:135-9. doi: 10.1111/j.1651-2227.1989.tb11294.x.
D-Penicillamine (DPA) was introduced to treat neonatal hyperbilirubinemia in 1973 and to prevent retinopathy of prematurity in 1980. In this study we investigated the renal and liver functions of neonates treated with DPA and the in vitro effect of the drug on superoxide anion generation and beta-glucuronidase release as well as phagocytic and intracellular killing activation of human peripheral blood granulocytes. Our data concerning the renal and liver functions before and after 3 to 4 days DPA treatment reveal that the drug does not produce any pathological change during short-term administration in the neonatal period. Furthermore, it was found that superoxide anion generation was slightly increased, and beta-glucuronidase release markedly increased by preincubation with DPA at concentrations of 0.5-5 mM. The rise was directly proportional to the concentration in the examined range. On the other hand, none of the examined DPA concentrations influenced the phagocytic or killing activity of neutrophils.
D-青霉胺（DPA）于1973年被用于治疗新生儿高胆红素血症，并于1980年用于预防早产儿视网膜病变。在本研究中，我们调查了接受DPA治疗的新生儿的肾功能和肝功能，以及该药物对超氧阴离子生成、β-葡萄糖醛酸酶释放的体外影响，以及对人外周血粒细胞吞噬和细胞内杀伤活性的影响。我们关于DPA治疗3至4天前后肾功能和肝功能的数据显示，该药物在新生儿期短期给药期间不会产生任何病理变化。此外，还发现，在0.5-5 mM浓度下与DPA预孵育后，超氧阴离子生成略有增加，β-葡萄糖醛酸酶释放显著增加。在所检查的范围内，这种增加与浓度成正比。另一方面，所检查的DPA浓度均未影响中性粒细胞的吞噬或杀伤活性。
